Loading
PTPRF (Receptor-type tyrosine-protein phosphatase F) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.
Possible cell adhesion receptor. It possesses an intrinsic protein tyrosine phosphatase activity (PTPase) and dephosphorylates EPHA2 regulating its activity. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one.
CIViC holds 2 clinical evidence items and 0 assertions across 1 variant, naming Erlotinib Hydrochloride.
In plain words · PTPRF (Receptor-type tyrosine-protein phosphatase F) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.
PTPRF (Receptor-type tyrosine-protein phosphatase F) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.
Possible cell adhesion receptor. It possesses an intrinsic protein tyrosine phosphatase activity (PTPase) and dephosphorylates EPHA2 regulating its activity.
No product in this corpus aims at PTPRF yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA PTPRF: RNA low tissue specificity; no normal tissue stained high; highest cancer staining endometrial cancer (3 of 11 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Lung cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas PTPRF tissue; Open Targets ENSG00000142949 associations
First described 1988. Earliest sequence paper UniProt cites for the protein: Streuli et al, J. Exp. Med, 1988, "A new member of the immunoglobulin superfamily that has a cytoplasmic region homologous to the leukocyte common antigen". Source.
Sources: HGNC HGNC:9670 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P10586 (protein name, function text, keywords and locations (REST API)); CIViC gene PTPRF (2 evidence items, 0 assertions, 1 variants; diseases: Lung Non-small Cell Carcinoma (GraphQL API, CC0))
Possible cell adhesion receptor. It possesses an intrinsic protein tyrosine phosphatase activity (PTPase) and dephosphorylates EPHA2 regulating its activity. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Location: Membrane (UniProt). Locus 1p34.2 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
No normal tissue stained high.
Medium only: glioma, lymphoma, melanoma, renal cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"PTPRF" OR ABSTRACT:"PTPRF" OR TITLE:"protein tyrosine phosphatase receptor type F" OR ABSTRACT:"protein tyrosine phosphatase receptor type F" OR TITLE:"Receptor-type tyrosine-protein phosphatase F" OR ABSTRACT:"Receptor-type tyrosine-protein phosphatase F") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PTPRF, not a curated reading list.